Niagen Bioscience Inc (NAGE)

$6.20 -0.30 (-4.62%)
Market Cap 509.96M
Revenue (ttm) 99.60M
Net Income (ttm) 8.55M
EPS (ttm) N/A
PE Ratio 40.75
Forward PE 22.23
Profit Margin 8.58%
Debt to Equity Ratio 0.00
Volume 567,548
Avg Vol 893,472
Day's Range N/A - N/A
Shares Out 79.81M
Stochastic %K 47%
Beta 2.35
Analysts Strong Sell
Price Target $15.25

Company Profile

Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+) test kits to healthcare practitioners; and develops and commercializes proprietary-based ingredient...

Industry: Biotechnology
Sector: Healthcare
Phone: 310 388 6706
Address:
10900 Wilshire Blvd, Suite 600, Los Angeles, United States
justiceforb_85
justiceforb_85 Jan. 14 at 7:12 PM
$NAGE continues to get hammered. Hopefully this starts to pick up soon.
0 · Reply
wycliff
wycliff Jan. 14 at 5:24 PM
$NAGE https://g.co/gemini/share/5b0d0deba365
0 · Reply
CarpSlayer
CarpSlayer Jan. 14 at 1:40 PM
$NAGE - NAD for Health: Opportunities & Challenges 2026 University of Copenhagen March 23-25 Great lineup of speakers including Dr. Tzoulis, Dr. Brenner, Dr. Bohr, Dr. Mcdermott, Dr. Martens, and many other relevant names. Sponsors include Niagen Bioscience, Metrobiotech, others https://eventsignup.ku.dk/nadforhealth/conference
1 · Reply
wycliff
wycliff Jan. 14 at 9:25 AM
$NAGE https://podwise.ai/dashboard/episodes/6784030
0 · Reply
wycliff
wycliff Jan. 14 at 8:39 AM
$NAGE record short interest Sets up for potential short squeeze on any future positive News releases
0 · Reply
Jimgym
Jimgym Jan. 13 at 2:28 PM
$NAGE short interest 5,674,234 A new all time high
2 · Reply
CarpSlayer
CarpSlayer Jan. 13 at 1:21 PM
$NAGE - 12 Jan 2026 1h 6m 541: Can a Pill Help You Live Longer? The Science Behind NAD and Longevity | Robert Fried https://podwise.ai/dashboard/episodes/6784030
3 · Reply
okeydokey_artichokey
okeydokey_artichokey Jan. 12 at 6:42 PM
$NAGE Ha. This was just published. (PNAS top tier journal). Here we see a potential confounder in diabetic of populations. Sirt3 is nad dependent, but its activity in hyperglycemia context accelerates axon degeneration while also contributing to nad depletion. Of course it's mice, but highlights difficulty of humans w high commorbidities. https://www.pnas.org/doi/10.1073/pnas.2517110123
1 · Reply
CarpSlayer
CarpSlayer Jan. 12 at 1:24 PM
$NAGE Nicotinamide riboside enhances liver regeneration via the MCART1/ASB3 axis in obesity-compromised rats January 2026 https://journals.lww.com/hepcomm/fulltext/2026/01010/nicotinamide_riboside_enhances_liver_regeneration.11.aspx
0 · Reply
MattManzanita
MattManzanita Jan. 11 at 9:20 PM
$NAGE https://pubmed.ncbi.nlm.nih.gov/41502156/
3 · Reply
Latest News on NAGE
Niagen Bioscience Acquires Existing Core Nicotinamide Riboside (NR) Patent Portfolio from Queen's University Belfast

Dec 22, 2025, 8:32 AM EST - 23 days ago

Niagen Bioscience Acquires Existing Core Nicotinamide Riboside (NR) Patent Portfolio from Queen's University Belfast

Niagen Bioscience: A Breakout Quarter That Now Faces Its Biggest Market Shift In Years

Nov 15, 2025, 5:41 AM EST - 2 months ago

Niagen Bioscience: A Breakout Quarter That Now Faces Its Biggest Market Shift In Years

Niagen Bioscience Launches Tru Niagen® Beauty — The First NAD+ Skincare Supplement in the U.S. Featuring Niagen® (Patented Nicotinamide Riboside)

Nov 13, 2025, 8:32 AM EST - 2 months ago

Niagen Bioscience Launches Tru Niagen® Beauty — The First NAD+ Skincare Supplement in the U.S. Featuring Niagen® (Patented Nicotinamide Riboside)

Niagen Bioscience Announces Results from First-Ever Randomized Controlled Trial Exploring Niagen (Patented Nicotinamide Riboside, NR) Supplementation in Long COVID

Nov 12, 2025, 7:52 PM EST - 2 months ago

Niagen Bioscience Announces Results from First-Ever Randomized Controlled Trial Exploring Niagen (Patented Nicotinamide Riboside, NR) Supplementation in Long COVID

Niagen Bioscience Announces $10 Million Share Repurchase Program

Nov 6, 2025, 8:07 AM EST - 2 months ago

Niagen Bioscience Announces $10 Million Share Repurchase Program

Niagen Bioscience, Inc. (NAGE) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 6:56 PM EST - 2 months ago

Niagen Bioscience, Inc. (NAGE) Q3 2025 Earnings Call Transcript

Niagen Bioscience, Inc. Reports Third Quarter 2025 Financial Results and Reaffirms Increased Full Year Outlook

Nov 4, 2025, 4:02 PM EST - 2 months ago

Niagen Bioscience, Inc. Reports Third Quarter 2025 Financial Results and Reaffirms Increased Full Year Outlook

Niagen Bioscience to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025

Oct 21, 2025, 8:32 AM EDT - 3 months ago

Niagen Bioscience to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025

Niagen Bioscience Increases Full Year 2025 Net Sales Outlook to 25% to 30% Year-Over-Year Growth

Oct 6, 2025, 8:32 AM EDT - 3 months ago

Niagen Bioscience Increases Full Year 2025 Net Sales Outlook to 25% to 30% Year-Over-Year Growth

Niagen Bioscience's Pharmaceutical-Grade Niagen™ IV and Injections Now Available at over 50 iCRYO Clinics and More than 900 Total Clinics Nationwide

Oct 1, 2025, 8:32 AM EDT - 3 months ago

Niagen Bioscience's Pharmaceutical-Grade Niagen™ IV and Injections Now Available at over 50 iCRYO Clinics and More than 900 Total Clinics Nationwide

AboutNADⓇ Debuts as the Leading Online Resource for Scientific Advancements in NAD+

Sep 16, 2025, 8:32 AM EDT - 4 months ago

AboutNADⓇ Debuts as the Leading Online Resource for Scientific Advancements in NAD+

Niagen Bioscience, Inc. Reports Second Quarter 2025 Financial Results and Increases Full Year Outlook

Aug 6, 2025, 4:02 PM EDT - 5 months ago

Niagen Bioscience, Inc. Reports Second Quarter 2025 Financial Results and Increases Full Year Outlook

Niagen Bioscience to Present at Canaccord Genuity's 45th Annual Growth Conference

Aug 4, 2025, 8:32 AM EDT - 5 months ago

Niagen Bioscience to Present at Canaccord Genuity's 45th Annual Growth Conference

Niagen Bioscience to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025

Jul 23, 2025, 8:34 AM EDT - 6 months ago

Niagen Bioscience to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025

Niagen Bioscience Announces the Debut of Tru Niagen® and Niagen IV at Equinox Hotel New York

Jul 14, 2025, 8:32 AM EDT - 6 months ago

Niagen Bioscience Announces the Debut of Tru Niagen® and Niagen IV at Equinox Hotel New York

Niagen Bioscience Secures Exclusive License to Develop and Commercialize its NAD+ Precursor, Patented Nicotinamide Riboside (Niagen®), as a Potential Parkinson's Disease Therapy in Agreement with Haukeland University Hospital in Bergen, Norway

Jul 8, 2025, 8:32 AM EDT - 6 months ago

Niagen Bioscience Secures Exclusive License to Develop and Commercialize its NAD+ Precursor, Patented Nicotinamide Riboside (Niagen®), as a Potential Parkinson's Disease Therapy in Agreement with Haukeland University Hospital in Bergen, Norway

Niagen Biosciences: Anti-Aging Market Leader And Prime Beneficiary Of Long-Term Demographic Trends

Jun 24, 2025, 4:27 PM EDT - 7 months ago

Niagen Biosciences: Anti-Aging Market Leader And Prime Beneficiary Of Long-Term Demographic Trends

Niagen Bioscience to Participate at the Roth 15th Annual London Conference

Jun 20, 2025, 8:32 AM EDT - 7 months ago

Niagen Bioscience to Participate at the Roth 15th Annual London Conference

Niagen Bioscience to Participate in the BIO 2025 International Convention

Jun 11, 2025, 8:31 AM EDT - 7 months ago

Niagen Bioscience to Participate in the BIO 2025 International Convention

Niagen Bioscience: High Conviction, High Expectations

Jun 11, 2025, 6:48 AM EDT - 7 months ago

Niagen Bioscience: High Conviction, High Expectations

Niagen Bioscience Announces First-Ever Peer-Reviewed Study Highlighting the Potential of Nicotinamide Riboside (NR) for Werner Syndrome, a Rare Genetic Disorder

Jun 9, 2025, 8:32 AM EDT - 7 months ago

Niagen Bioscience Announces First-Ever Peer-Reviewed Study Highlighting the Potential of Nicotinamide Riboside (NR) for Werner Syndrome, a Rare Genetic Disorder

Niagen Bioscience to Present at Oppenheimer's 25th Annual Consumer Growth and E-Commerce Conference

Jun 4, 2025, 8:32 AM EDT - 8 months ago

Niagen Bioscience to Present at Oppenheimer's 25th Annual Consumer Growth and E-Commerce Conference

Niagen Bioscience, Inc. (NAGE) Q1 202 Earnings Call Transcript

May 10, 2025, 1:40 PM EDT - 8 months ago

Niagen Bioscience, Inc. (NAGE) Q1 202 Earnings Call Transcript

Niagen Bioscience, Inc. Reports First Quarter 2025 Financial Results and Increases Outlook

May 7, 2025, 4:02 PM EDT - 8 months ago

Niagen Bioscience, Inc. Reports First Quarter 2025 Financial Results and Increases Outlook

Niagen Bioscience Announces Pharmaceutical-Grade Niagen® IV Is Now Available in Almost 600 Clinics Nationwide

May 5, 2025, 8:32 AM EDT - 9 months ago

Niagen Bioscience Announces Pharmaceutical-Grade Niagen® IV Is Now Available in Almost 600 Clinics Nationwide

Niagen Bioscience Welcomes Dr. Pinchas Cohen to Scientific Advisory Board

Apr 29, 2025, 8:32 AM EDT - 9 months ago

Niagen Bioscience Welcomes Dr. Pinchas Cohen to Scientific Advisory Board

Niagen Bioscience to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025

Apr 28, 2025, 8:34 AM EDT - 9 months ago

Niagen Bioscience to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025

Niagen Bioscience Confirms Its Operations Remain Unaffected by New Tariffs

Apr 7, 2025, 10:32 PM EDT - 10 months ago

Niagen Bioscience Confirms Its Operations Remain Unaffected by New Tariffs

Niagen Bioscience Confirms Its Operations Remain Resilient Amid New Tariff Developments

Apr 7, 2025, 8:32 AM EDT - 10 months ago

Niagen Bioscience Confirms Its Operations Remain Resilient Amid New Tariff Developments

Niagen Bioscience Secures U.S. Patent for the Composition of Matter for Nicotinamide Riboside (NR) Salt Forms

Mar 20, 2025, 8:34 AM EDT - 10 months ago

Niagen Bioscience Secures U.S. Patent for the Composition of Matter for Nicotinamide Riboside (NR) Salt Forms

ChromaDex Evolves Into Niagen Bioscience, Marking a New Era of Uncovering the Potential of NAD+ With Precision Science

Mar 19, 2025, 8:34 AM EDT - 10 months ago

ChromaDex Evolves Into Niagen Bioscience, Marking a New Era of Uncovering the Potential of NAD+ With Precision Science

ChromaDex Corp. Announces Name Change to Niagen Bioscience, Inc. and New Ticker Symbol "NAGE" Effective March 19, 2025

Mar 13, 2025, 8:34 AM EDT - 10 months ago

ChromaDex Corp. Announces Name Change to Niagen Bioscience, Inc. and New Ticker Symbol "NAGE" Effective March 19, 2025

ChromaDex to Present at the 37th Annual Roth Conference

Mar 11, 2025, 4:04 PM EDT - 11 months ago

ChromaDex to Present at the 37th Annual Roth Conference

ChromaDex Capitalizes On Longevity Boom But Valuation Remains High

Mar 6, 2025, 10:30 AM EST - 11 months ago

ChromaDex Capitalizes On Longevity Boom But Valuation Remains High

ChromaDex Corporation (CDXC) Q4 2024 Earnings Call Transcript

Mar 4, 2025, 8:53 PM EST - 11 months ago

ChromaDex Corporation (CDXC) Q4 2024 Earnings Call Transcript

ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2024 Results

Mar 4, 2025, 4:02 PM EST - 11 months ago

ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2024 Results

ChromaDex to Report Fourth Quarter and Fiscal Year 2024 Financial Results on Tuesday, March 4, 2025

Feb 25, 2025, 4:07 PM EST - 11 months ago

ChromaDex to Report Fourth Quarter and Fiscal Year 2024 Financial Results on Tuesday, March 4, 2025

ChromaDex to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

Jan 6, 2025, 8:32 AM EST - 1 year ago

ChromaDex to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

ChromaDex Named to the Inc. 2024 Best in Business List in the Health Products Category

Dec 3, 2024, 8:34 AM EST - 1 year ago

ChromaDex Named to the Inc. 2024 Best in Business List in the Health Products Category

ChromaDex's Patented Nicotinamide Riboside (NR) Ingredient, Niagen®, Featured as the Hero Ingredient in Longevity.Technology's Inaugural Longevity Supplement

Nov 14, 2024, 8:32 AM EST - 1 year ago

ChromaDex's Patented Nicotinamide Riboside (NR) Ingredient, Niagen®, Featured as the Hero Ingredient in Longevity.Technology's Inaugural Longevity Supplement

ChromaDex's Pharmaceutical-Grade Niagen® IV Now Accessible at over 200 Restore Hyper Wellness Clinics Nationwide

Nov 7, 2024, 8:32 AM EST - 1 year ago

ChromaDex's Pharmaceutical-Grade Niagen® IV Now Accessible at over 200 Restore Hyper Wellness Clinics Nationwide

ChromaDex Corporation (CDXC) Q3 2024 Earnings Call Transcript

Nov 1, 2024, 2:48 PM EDT - 1 year ago

ChromaDex Corporation (CDXC) Q3 2024 Earnings Call Transcript

ChromaDex Corporation Reports Third Quarter 2024 Financial Results

Oct 31, 2024, 4:04 PM EDT - 1 year ago

ChromaDex Corporation Reports Third Quarter 2024 Financial Results

ChromaDex to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024

Oct 28, 2024, 8:32 AM EDT - 1 year ago

ChromaDex to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024

ChromaDex to Participate in the 17th Annual LD Micro Main Event

Oct 23, 2024, 8:34 AM EDT - 1 year ago

ChromaDex to Participate in the 17th Annual LD Micro Main Event

Yasmeen Nkrumah-Elie, Ph.D., Global Director of External Research at ChromaDex, Honored with the Trailblazing Woman Award by Radicle Science and Council for Responsible Nutrition (CRN)

Oct 15, 2024, 8:32 AM EDT - 1 year ago

Yasmeen Nkrumah-Elie, Ph.D., Global Director of External Research at ChromaDex, Honored with the Trailblazing Woman Award by Radicle Science and Council for Responsible Nutrition (CRN)

ChromaDex to Participate in a Fireside Chat at the Lytham Partners Fall 2024 Investor Conference

Sep 26, 2024, 4:12 PM EDT - 1 year ago

ChromaDex to Participate in a Fireside Chat at the Lytham Partners Fall 2024 Investor Conference

ChromaDex Appoints Ozan Pamir as Chief Financial Officer

Sep 20, 2024, 8:32 AM EDT - 1 year ago

ChromaDex Appoints Ozan Pamir as Chief Financial Officer

ChromaDex Announces Expansion of Pharmaceutical-Grade Niagen® IV and Injection Offerings to Additional Leading Wellness Clinics

Sep 10, 2024, 8:32 AM EDT - 1 year ago

ChromaDex Announces Expansion of Pharmaceutical-Grade Niagen® IV and Injection Offerings to Additional Leading Wellness Clinics

ChromaDex Celebrates 25 Years of Innovation and Pioneering NAD+ Research for Healthy Aging Solutions

Sep 9, 2024, 8:34 AM EDT - 1 year ago

ChromaDex Celebrates 25 Years of Innovation and Pioneering NAD+ Research for Healthy Aging Solutions

justiceforb_85
justiceforb_85 Jan. 14 at 7:12 PM
$NAGE continues to get hammered. Hopefully this starts to pick up soon.
0 · Reply
wycliff
wycliff Jan. 14 at 5:24 PM
$NAGE https://g.co/gemini/share/5b0d0deba365
0 · Reply
CarpSlayer
CarpSlayer Jan. 14 at 1:40 PM
$NAGE - NAD for Health: Opportunities & Challenges 2026 University of Copenhagen March 23-25 Great lineup of speakers including Dr. Tzoulis, Dr. Brenner, Dr. Bohr, Dr. Mcdermott, Dr. Martens, and many other relevant names. Sponsors include Niagen Bioscience, Metrobiotech, others https://eventsignup.ku.dk/nadforhealth/conference
1 · Reply
wycliff
wycliff Jan. 14 at 9:25 AM
$NAGE https://podwise.ai/dashboard/episodes/6784030
0 · Reply
wycliff
wycliff Jan. 14 at 8:39 AM
$NAGE record short interest Sets up for potential short squeeze on any future positive News releases
0 · Reply
Jimgym
Jimgym Jan. 13 at 2:28 PM
$NAGE short interest 5,674,234 A new all time high
2 · Reply
CarpSlayer
CarpSlayer Jan. 13 at 1:21 PM
$NAGE - 12 Jan 2026 1h 6m 541: Can a Pill Help You Live Longer? The Science Behind NAD and Longevity | Robert Fried https://podwise.ai/dashboard/episodes/6784030
3 · Reply
okeydokey_artichokey
okeydokey_artichokey Jan. 12 at 6:42 PM
$NAGE Ha. This was just published. (PNAS top tier journal). Here we see a potential confounder in diabetic of populations. Sirt3 is nad dependent, but its activity in hyperglycemia context accelerates axon degeneration while also contributing to nad depletion. Of course it's mice, but highlights difficulty of humans w high commorbidities. https://www.pnas.org/doi/10.1073/pnas.2517110123
1 · Reply
CarpSlayer
CarpSlayer Jan. 12 at 1:24 PM
$NAGE Nicotinamide riboside enhances liver regeneration via the MCART1/ASB3 axis in obesity-compromised rats January 2026 https://journals.lww.com/hepcomm/fulltext/2026/01010/nicotinamide_riboside_enhances_liver_regeneration.11.aspx
0 · Reply
MattManzanita
MattManzanita Jan. 11 at 9:20 PM
$NAGE https://pubmed.ncbi.nlm.nih.gov/41502156/
3 · Reply
okeydokey_artichokey
okeydokey_artichokey Jan. 9 at 2:08 PM
$NAGE Intravenous NAD+ as an Adjunct to IVF in Diminished Ovarian Reserve: The first Indian within-Subject (Before-After) Study of Oocyte Yield, Oocyte Competence, and Day-3 Embryo Quality https://www.researchgate.net/profile/Sunita-Tandulwadkar/publication/399481415_Intravenous_NAD_as_an_Adjunct_to_IVF_in_Diminished_Ovarian_Reserve_The_first_Indian_within-Subject_Before-After_Study_of_Oocy_te_Yield_Oocy_te_Competence_and_Day-3_Embryo_Quality/links/695c9de6a1fd01798911314a/Intravenous-NAD-as-an-Adjunct-to-IVF-in-Diminished-Ovarian-Reserve-The-first-Indian-within-Subject-Before-After-Study-of-Oocy-te-Yield-Oocy-te-Competence-and-Day-3-Embryo-Quality.pdf
0 · Reply
okeydokey_artichokey
okeydokey_artichokey Jan. 9 at 2:03 PM
$NAGE https://www.frontiersin.org/journals/aging/articles/10.3389/fragi.2026.1652582/abstract
1 · Reply
MattManzanita
MattManzanita Jan. 8 at 7:23 PM
$NAGE I think this is a new clinical trial being started in Norway: The NADage Study (NCT06208527) is a single-center, double-blind, randomized, placebo-controlled Phase II clinical trial investigating the effect of high-dose nicotinamide riboside (NR) supplementation in elderly, frail individuals. Study Details Official Title: The NADage Study: Nicotinamide Riboside Replenishment Therapy Against Functional Decline in Aging. Status: The study is currently Recruiting participants. Intervention: Participants are randomized into two groups (1:1 ratio) to receive either 2000 mg of nicotinamide riboside (NR) daily or a placebo for 52 weeks. Location: The study is being conducted at Helse Bergen in Norway. Sponsor/Collaborators: Helse Bergen (Bergen Hospital Trust) is the listed sponsor. Study Objectives The main goal of the study is to determine if NR supplementation can slow down the functional decline associated with aging and frailty by boosting cellular NAD+ levels.
2 · Reply
wycliff
wycliff Jan. 7 at 11:53 AM
$NAGE https://athletechnews.com/most-popular-wellness-supplement-nutrition-brands-best-products-2025/
0 · Reply
LyraDuarteWn
LyraDuarteWn Jan. 7 at 5:59 AM
$NAGE microcap low attention, tight range coil, volume ignition can move it fast on thin supply
0 · Reply
stupidusername
stupidusername Jan. 6 at 9:17 PM
$NAGE I looked at the NCT for long covid and it was results out approximately 4-5 months from completion. We are over 6 months on Parkinson’s completion now.
1 · Reply
Rainmaker64
Rainmaker64 Jan. 6 at 9:09 PM
$NAGE It looks like the highest daily volume (1.25M) since early November if my E*Trade chart is accurate.
0 · Reply
stupidusername
stupidusername Jan. 6 at 8:22 PM
$NAGE small pump end of day
0 · Reply
Impalas283
Impalas283 Jan. 6 at 7:18 PM
$NAGE One of the things that give me confidence is the amount of institutional ownership. Maybe they know something we don't.
1 · Reply
CarpSlayer
CarpSlayer Jan. 6 at 1:46 PM
$NAGE - Niagen Bioscience: Why Discipline Matters In A Crowded Supplement Market Interview with Rob is basis for updated analysis largely regarding the Niagen and Niagen Plus markets, but ignores the opportunity presented by NOPARK. https://seekingalpha.com/article/4857281-niagen-bioscience-why-discipline-matters-in-a-crowded-supplement-market?source=generic_rss
1 · Reply
DipTorchX_1443
DipTorchX_1443 Jan. 6 at 11:27 AM
$NAGE microcap low attention, tight range coil, volume ignition can move it fast on thin supply
0 · Reply
nhadar
nhadar Jan. 5 at 11:46 PM
$NAGE we need to move in the peptide direction
0 · Reply